+

WO2001059063A3 - Acides nucleiques, proteines et anticorps - Google Patents

Acides nucleiques, proteines et anticorps Download PDF

Info

Publication number
WO2001059063A3
WO2001059063A3 PCT/US2001/001334 US0101334W WO0159063A3 WO 2001059063 A3 WO2001059063 A3 WO 2001059063A3 US 0101334 W US0101334 W US 0101334W WO 0159063 A3 WO0159063 A3 WO 0159063A3
Authority
WO
WIPO (PCT)
Prior art keywords
nervous system
polypeptides
polynucleotides
methods
further relates
Prior art date
Application number
PCT/US2001/001334
Other languages
English (en)
Other versions
WO2001059063A2 (fr
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M Ruben filed Critical Human Genome Sciences Inc
Priority to EP01924085A priority Critical patent/EP1261745A2/fr
Priority to US09/908,711 priority patent/US20020045230A1/en
Publication of WO2001059063A2 publication Critical patent/WO2001059063A2/fr
Publication of WO2001059063A3 publication Critical patent/WO2001059063A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux polynucléotides liés au système nerveux et les polypeptides codés par ces polynucléotides qu'on appelle collectivement 'antigènes du système nerveux'' et l'utilisation de ces mêmes antigènes du système nerveux pour détecter des troubles du système nerveux, particulièrement la présence de cancers du système nerveux et les métastases cancéreuses du système nerveux. De manière plus spécifique, on décrit des molécules d'acide nucléique isolées associées au système nerveux qui codent de nouveaux polypeptides associés au système nerveux ; de nouveaux polypeptides du système nerveux et des anticorps qui se lient à ces polypeptides ainsi que des vecteurs, des cellules hôtes et des procédés de recombinaison et de synthèse utiles pour produire les polynucléotides et/ou les polypeptides associés au système nerveux. La présente invention concerne également des procédés de diagnostic et de thérapie utiles pour diagnostiquer, traiter, prévenir et/ou pronostiquer des troubles liés au système nerveux, y compris les cancers du système nerveux et des procédés de thérapie utilisés pour traiter ces troubles; un procédé de criblage qui permet d'identifier des agonistes et des antagonistes des polynucléotides et des polypeptides selon l'invention; et des procédés et/ou des compositions permettant d'inhiber la production et le fonctionnement des peptides selon la présente invention.
PCT/US2001/001334 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps WO2001059063A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01924085A EP1261745A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps
US09/908,711 US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Applications Claiming Priority (234)

Application Number Priority Date Filing Date Title
US17906500P 2000-01-31 2000-01-31
US60/179,065 2000-01-31
US18062800P 2000-02-04 2000-02-04
US60/180,628 2000-02-04
US18466400P 2000-02-24 2000-02-24
US60/184,664 2000-02-24
US18635000P 2000-03-02 2000-03-02
US60/186,350 2000-03-02
US18987400P 2000-03-16 2000-03-16
US60/189,874 2000-03-16
US19007600P 2000-03-17 2000-03-17
US60/190,076 2000-03-17
US19812300P 2000-04-18 2000-04-18
US60/198,123 2000-04-18
US20551500P 2000-05-19 2000-05-19
US60/205,515 2000-05-19
US20946700P 2000-06-07 2000-06-07
US60/209,467 2000-06-07
US21488600P 2000-06-28 2000-06-28
US60/214,886 2000-06-28
US21513500P 2000-06-30 2000-06-30
US60/215,135 2000-06-30
US21688000P 2000-07-07 2000-07-07
US21664700P 2000-07-07 2000-07-07
US60/216,880 2000-07-07
US60/216,647 2000-07-07
US21748700P 2000-07-11 2000-07-11
US21749600P 2000-07-11 2000-07-11
US60/217,487 2000-07-11
US60/217,496 2000-07-11
US21829000P 2000-07-14 2000-07-14
US60/218,290 2000-07-14
US22096400P 2000-07-26 2000-07-26
US22096300P 2000-07-26 2000-07-26
US60/220,964 2000-07-26
US60/220,963 2000-07-26
US22451900P 2000-08-14 2000-08-14
US22575800P 2000-08-14 2000-08-14
US22451800P 2000-08-14 2000-08-14
US22575900P 2000-08-14 2000-08-14
US22521400P 2000-08-14 2000-08-14
US22527000P 2000-08-14 2000-08-14
US22526800P 2000-08-14 2000-08-14
US22575700P 2000-08-14 2000-08-14
US22526700P 2000-08-14 2000-08-14
US22526600P 2000-08-14 2000-08-14
US22544700P 2000-08-14 2000-08-14
US22521300P 2000-08-14 2000-08-14
US60/225,213 2000-08-14
US60/225,758 2000-08-14
US60/225,268 2000-08-14
US60/225,757 2000-08-14
US60/224,519 2000-08-14
US60/225,267 2000-08-14
US60/224,518 2000-08-14
US60/225,447 2000-08-14
US60/225,759 2000-08-14
US60/225,270 2000-08-14
US60/225,266 2000-08-14
US60/225,214 2000-08-14
US22627900P 2000-08-18 2000-08-18
US60/226,279 2000-08-18
US22718200P 2000-08-22 2000-08-22
US22668100P 2000-08-22 2000-08-22
US22686800P 2000-08-22 2000-08-22
US60/226,868 2000-08-22
US60/227,182 2000-08-22
US60/226,681 2000-08-22
US22700900P 2000-08-23 2000-08-23
US60/227,009 2000-08-23
US22892400P 2000-08-30 2000-08-30
US60/228,924 2000-08-30
US22934400P 2000-09-01 2000-09-01
US22928700P 2000-09-01 2000-09-01
US22934300P 2000-09-01 2000-09-01
US22934500P 2000-09-01 2000-09-01
US60/229,345 2000-09-01
US60/229,344 2000-09-01
US60/229,287 2000-09-01
US60/229,343 2000-09-01
US22951300P 2000-09-05 2000-09-05
US22950900P 2000-09-05 2000-09-05
US60/229,509 2000-09-05
US60/229,513 2000-09-05
US23043700P 2000-09-06 2000-09-06
US23043800P 2000-09-06 2000-09-06
US60/230,437 2000-09-06
US60/230,438 2000-09-06
US23124300P 2000-09-08 2000-09-08
US23208100P 2000-09-08 2000-09-08
US23124200P 2000-09-08 2000-09-08
US23141300P 2000-09-08 2000-09-08
US23124400P 2000-09-08 2000-09-08
US23208000P 2000-09-08 2000-09-08
US23141400P 2000-09-08 2000-09-08
US60/231,242 2000-09-08
US60/232,081 2000-09-08
US60/231,413 2000-09-08
US60/231,243 2000-09-08
US60/231,414 2000-09-08
US60/231,244 2000-09-08
US60/232,080 2000-09-08
US23196800P 2000-09-12 2000-09-12
US60/231,968 2000-09-12
US23239900P 2000-09-14 2000-09-14
US23239700P 2000-09-14 2000-09-14
US23306300P 2000-09-14 2000-09-14
US23306500P 2000-09-14 2000-09-14
US23240000P 2000-09-14 2000-09-14
US23240100P 2000-09-14 2000-09-14
US23306400P 2000-09-14 2000-09-14
US23239800P 2000-09-14 2000-09-14
US60/232,400 2000-09-14
US60/232,397 2000-09-14
US60/233,065 2000-09-14
US60/232,399 2000-09-14
US60/233,063 2000-09-14
US60/232,401 2000-09-14
US60/233,064 2000-09-14
US60/232,398 2000-09-14
US23427400P 2000-09-21 2000-09-21
US23422300P 2000-09-21 2000-09-21
US60/234,223 2000-09-21
US60/234,274 2000-09-21
US23499800P 2000-09-25 2000-09-25
US23499700P 2000-09-25 2000-09-25
US60/234,997 2000-09-25
US60/234,998 2000-09-25
US23548400P 2000-09-26 2000-09-26
US60/235,484 2000-09-26
US23583400P 2000-09-27 2000-09-27
US23583600P 2000-09-27 2000-09-27
US60/235,836 2000-09-27
US60/235,834 2000-09-27
US23636800P 2000-09-29 2000-09-29
US23636700P 2000-09-29 2000-09-29
US23632700P 2000-09-29 2000-09-29
US23637000P 2000-09-29 2000-09-29
US23636900P 2000-09-29 2000-09-29
US60/236,370 2000-09-29
US60/236,368 2000-09-29
US60/236,369 2000-09-29
US60/236,327 2000-09-29
US60/236,367 2000-09-29
US23680200P 2000-10-02 2000-10-02
US23703900P 2000-10-02 2000-10-02
US23704000P 2000-10-02 2000-10-02
US23703700P 2000-10-02 2000-10-02
US23703800P 2000-10-02 2000-10-02
US60/236,802 2000-10-02
US60/237,037 2000-10-02
US60/237,039 2000-10-02
US60/237,040 2000-10-02
US60/237,038 2000-10-02
US23993700P 2000-10-13 2000-10-13
US23993500P 2000-10-13 2000-10-13
US60/239,935 2000-10-13
US60/239,937 2000-10-13
US24180900P 2000-10-20 2000-10-20
US24096000P 2000-10-20 2000-10-20
US24178700P 2000-10-20 2000-10-20
US24182600P 2000-10-20 2000-10-20
US24178600P 2000-10-20 2000-10-20
US24180800P 2000-10-20 2000-10-20
US24178500P 2000-10-20 2000-10-20
US60/241,809 2000-10-20
US60/241,786 2000-10-20
US60/240,960 2000-10-20
US60/241,826 2000-10-20
US60/241,808 2000-10-20
US60/241,785 2000-10-20
US60/241,787 2000-10-20
US60/242,221 2000-10-20
US24461700P 2000-11-01 2000-11-01
US60/244,617 2000-11-01
US24661300P 2000-11-08 2000-11-08
US24652800P 2000-11-08 2000-11-08
US24661100P 2000-11-08 2000-11-08
US24652600P 2000-11-08 2000-11-08
US24661000P 2000-11-08 2000-11-08
US24647600P 2000-11-08 2000-11-08
US24647700P 2000-11-08 2000-11-08
US24647500P 2000-11-08 2000-11-08
US24647400P 2000-11-08 2000-11-08
US24652500P 2000-11-08 2000-11-08
US24653200P 2000-11-08 2000-11-08
US60/246,525 2000-11-08
US60/246,476 2000-11-08
US60/246,527 2000-11-08
US60/246,523 2000-11-08
US60/246,528 2000-11-08
US60/246,526 2000-11-08
US60/246,475 2000-11-08
US60/246,532 2000-11-08
US60/246,474 2000-11-08
US60/246,613 2000-11-08
US60/246,477 2000-11-08
US60/246,611 2000-11-08
US60/246,524 2000-11-08
US60/246,610 2000-11-08
US60/246,609 2000-11-08
US60/246,478 2000-11-08
US60/249,211 2000-11-17
US60/249,217 2000-11-17
US60/249,244 2000-11-17
US60/249,300 2000-11-17
US60/249,264 2000-11-17
US60/249,208 2000-11-17
US60/249,214 2000-11-17
US60/249,215 2000-11-17
US60/249,216 2000-11-17
US60/249,210 2000-11-17
US60/249,297 2000-11-17
US60/249,245 2000-11-17
US60/249,218 2000-11-17
US60/249,207 2000-11-17
US60/249,265 2000-11-17
US60/249,213 2000-11-17
US60/249,299 2000-11-17
US60/249,212 2000-11-17
US60/249,209 2000-11-17
US60/250,391 2000-12-01
US60/251,160 2000-12-01
US60/251,988 2000-12-05
US60/251,030 2000-12-05
US60/256,719 2000-12-05
US60/251,479 2000-12-06
US60/251,990 2000-12-08
US60/251,868 2000-12-08
US60/251,856 2000-12-08
US60/251,869 2000-12-08
US60/251,989 2000-12-08
US60/254,097 2000-12-11
US60/259,678 2001-01-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/908,711 Continuation-In-Part US20020045230A1 (en) 2000-08-14 2001-07-20 Nucleic acids, proteins, and antibodies

Publications (2)

Publication Number Publication Date
WO2001059063A2 WO2001059063A2 (fr) 2001-08-16
WO2001059063A3 true WO2001059063A3 (fr) 2002-07-04

Family

ID=39591481

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/001334 WO2001059063A2 (fr) 2000-01-31 2001-01-17 Acides nucleiques, proteines et anticorps

Country Status (2)

Country Link
AU (1) AU5077101A (fr)
WO (1) WO2001059063A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591452B1 (fr) * 1999-03-23 2008-05-21 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
WO2002060953A2 (fr) 2000-12-15 2002-08-08 Agensys, Inc. Acide nucleique et proteine transporteur de zinc codee intitules 108p5h8 utiles dans le traitement et la detection du cancer
US6664084B2 (en) * 2001-02-26 2003-12-16 Applera Corporation Isolated nucleic acid molecules encoding human glucuronyltransferase proteins, and related products and processes
AT410945B (de) * 2001-06-27 2003-08-25 Burkhard Dr Jansen Verfahren zur diagnose von multipler sklerose (ms)
US20030068691A1 (en) * 2001-07-16 2003-04-10 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
GB2399086A (en) * 2001-08-02 2004-09-08 Aeomica Inc Human zinc finger containing gene MDZ4
WO2003018793A1 (fr) * 2001-08-23 2003-03-06 Shionogi & Co., Ltd. Nouveau gene presentant une sequence de type facteur d'echange de nucleotides guanyliques
WO2003020954A2 (fr) 2001-08-31 2003-03-13 Agensys, Inc. Acide nucleique et proteine correspondante appelee 205p1b5 utilises dans le traitement et la detection du cancer
WO2003023034A2 (fr) * 2001-09-12 2003-03-20 Bayer Healthcare Ag Regulation de tau-tubuline kinase humaine
WO2003025175A2 (fr) * 2001-09-17 2003-03-27 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
US7396922B2 (en) * 2001-11-28 2008-07-08 Angiogenetics Sweden Ab Regulation of hypoxia-inducible gene expression with antisense Inhibitory PAS domain protein
JP2003250550A (ja) * 2002-02-25 2003-09-09 Nissui Pharm Co Ltd 脂肪細胞分化関連遺伝子およびタンパク質
AU2003236041A1 (en) * 2002-04-12 2003-10-27 Takeda Chemical Industries, Ltd. Novel protein and dna thereof
JP2004041003A (ja) * 2002-05-17 2004-02-12 Takeda Chem Ind Ltd 新規タンパク質、そのｄｎａおよびその用途
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
EP1398372A1 (fr) * 2002-09-13 2004-03-17 Universitätsklinikum Charité an der Humboldt- Universität zu Berlin Lipid phosphate phosphatases et leur utilisation pour le traitement des maladies neuronales
GEP20094629B (en) 2003-03-19 2009-03-10 Biogen Idec Inc Nogo receptor binding protein
US20130171178A1 (en) * 2003-12-12 2013-07-04 The Government Of The United States As Represented By The Secretary Of Health And Human Services Immunogenic Peptides of Xage-1
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005085861A2 (fr) * 2004-03-03 2005-09-15 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Acides nucleiques et polypeptides codes destines a etre utilises dans des troubles hepatiques et du cancer epithelial
RS52593B (en) 2004-06-24 2013-04-30 Biogen Idec Ma Inc. TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION
CA2902070A1 (fr) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Anticorps anti-sp35 et leurs utilisations
JP2009505631A (ja) * 2005-07-28 2009-02-12 オンコセラピー・サイエンス株式会社 癌関連遺伝子ｒａｓｇｅｆ１ａ
CA2643737C (fr) 2006-03-13 2020-05-05 Mubio Products Bv Vaccin contre le cancer
US20100112568A1 (en) * 2006-12-29 2010-05-06 Tel Hashomer Medical Research Infrastructure And S Methods and kits for diagnosis of multiple sclerosis in probable multiple sclerosis subjects
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US8999634B2 (en) * 2007-04-27 2015-04-07 Quest Diagnostics Investments Incorporated Nucleic acid detection combining amplification with fragmentation
EP2982695B1 (fr) 2008-07-09 2019-04-03 Biogen MA Inc. Compositions comprenant des anticorps anti-lingo ou leurs fragments
US9175353B2 (en) 2008-11-14 2015-11-03 Gen-Probe Incorporated Compositions, kits and methods for detection of campylobacter nucleic acid
CA2873623C (fr) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
US10435467B2 (en) 2015-01-08 2019-10-08 Biogen Ma Inc. LINGO-1 antagonists and uses for treatment of demyelinating disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE NCBI [online] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION, NATIONAL LIBRARY OF MEDICINE, NIH (BETHESDA, MD, USA); 20 October 1999 (1999-10-20), HATTORI M. ET AL., XP002947519, Database accession no. AP000624.2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7628989B2 (en) 2001-04-10 2009-12-08 Agensys, Inc. Methods of inducing an immune response
US7641905B2 (en) 2001-04-10 2010-01-05 Agensys, Inc. Methods of inducing an immune response

Also Published As

Publication number Publication date
WO2001059063A2 (fr) 2001-08-16
AU5077101A (en) 2001-08-20

Similar Documents

Publication Publication Date Title
WO2001059063A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055320A3 (fr) Acides nucleiques, proteines et anticorps
WO2002000677A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055317A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055300A8 (fr) Acides nucleiques, proteines et anticorps
WO2001055313A3 (fr) Acides nucleiques, proteines et anticorps
WO2001055329A3 (fr) Acides nucleiques, proteines et anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001924085

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001924085

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001924085

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载